Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

192.57 +2.05 (+1.08%)
Streaming Delayed Price Updated: 2:24 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
41 42 Next >
Here's How Much $1000 Invested In Biogen 20 Years Ago Would Be Worth Today
Via Benzinga
Industry Comparison: Evaluating Biogen Against Competitors In Biotechnology Industry
Via Benzinga
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
The major indexes ended long win streaks. Datadog led earnings winners. 
Via Investor's Business Daily
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
The real competitive battle is about to begin, and it will last a long time. 
Via The Motley Fool
Expert Ratings for Biogen
Via Benzinga
Looking Into Biogen's Recent Short Interest
Via Benzinga
Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years
Via Benzinga
These Analysts Revise Their Forecasts On Biogen After Q3 Results
Biogen Inc (NASDAQ: BIIB) reported better-than-expected third-quarter earnings. 
Via Benzinga
Thoughts For Thursday: Staying On Top - Barely
The stock market continues to be full of worry, but is managing to stay on top this week, so far. It is worth noting that yesterday's close brought levels back to those of a month ago. 
Via Talk Markets
Biogen (BIIB) Q3 2023 Earnings Call Transcript
BIIB earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Biogen Revises Annual Forecast As Reata M&A And Alzheimer's Drug Expenses Hit Bottomline, Stock Slides
Biogen Inc (NASDAQ: BIIB) posted Q3 FY23 sales of $2.53 billion, beating the con 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Assessing Biogen's Performance Against Competitors In Biotechnology Industry
Via Benzinga
$1000 Invested In Biogen 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Inquiry Into Biogen's Competitor Dynamics In Biotechnology Industry
Via Benzinga
Compared To Estimates, Biogen Inc. Q3 Earnings: A Look At Key Metrics
Biogen Inc. reported $2.53 billion in revenue for the quarter ended September 2023. 
Via Talk Markets
US Stocks Set To Open Flat After Hot 7-Day Rally: Traders Sharpen Focus On Powell's Speech, Disney Earnings
Stock futures indicate a subdued opening on Wednesday after several consecutive gains in major averages. Traders are eagerly awaiting Federal Reserve Chair Jerome Powell’s speech for insights into... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Biogen Tops Earnings Forecasts, But Cuts Profit Outlook As Leqembi Expenses Mount
The company shares in the profits and sales related to Alzheimer's treatment, Leqembi. 
Via Investor's Business Daily
3 Biotech Moonshots to Bet on the Future of Health
Thanks to their potential blockbuster drugs, these three biotech stocks may yield huge returns for patent investors willing to take the risk. 
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
BIIB Stock Price Analysis: To Bet Or To Fold The Cards
Massachusetts-based Biogen (BIIB​​​​​​​) is a global biotechnology leader, researching and developing therapies for debilitating diseases impacting the central nervous system. 
Via Talk Markets
Biogen Appoints Monish Patolawala to its Board of Directors
Accomplished executive brings deep expertise leading global financial organizations and overseeing successful business transformation 
From Biogen Inc.
Via GlobeNewswire
Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment
Both companies are working on under-the-skin injections for Alzheimer's treatment. 
Via Investor's Business Daily
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On
From Biogen Inc.
Via GlobeNewswire
Biogen Says New Data Shows Promise For Potential New Generation Of Treatments In Early Alzheimer's Disease
Biogen Inc. (NASDAQ: BIIB) reported new Phase 1b clinical data from the study of BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, 
Via Benzinga
New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
An Oversold Small Cap Industrial That Insiders Are Buying Ahead Of Earnings This Week
Another RSI Buy In a post last month, we wrote about the power of RSI (Relative Strength Index) as a technical indicator (Relative Strength Index) in relation to Stitch Fix, Inc. (NASDAQ: SFIX)  
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting
From Biogen Inc.
Via GlobeNewswire
3 Struggling Stocks Investors Shouldn't Buy on the Dip
These stocks have been brutal investments to own in recent years -- and investors shouldn't expect things to get better. 
Via The Motley Fool
Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage
The U.S. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
41 42 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.